May 24, 2023 7:00am EDT XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
Apr 21, 2023 7:00am EDT XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Polycystic Kidney Disease
Feb 01, 2023 7:00am EST XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease
Jan 03, 2023 7:00am EST XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression